What is SouthernBiotech?
Established in 1982, SouthernBiotech has evolved into a cornerstone provider of high-quality antibodies essential for diagnostics, drug development, and complex discovery studies. The company distinguishes itself through a robust portfolio of primary and secondary antibodies, alongside specialized immunoreagents. By maintaining in-house production and rigorous validation protocols, SouthernBiotech ensures the reliability required by academic and commercial researchers alike. Their commitment to customizable solutions and responsive technical support has allowed them to maintain a competitive edge in the life sciences sector for over four decades, effectively bridging the gap between raw biological research and clinical application.
How much funding has SouthernBiotech raised?
SouthernBiotech has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in SouthernBiotech
PPP
Public-Private Partnership
What's next for SouthernBiotech?
With the successful acquisition of this late-stage capital, SouthernBiotech is well-positioned to accelerate its growth trajectory. The strategic deployment of these funds will likely focus on scaling production capabilities to meet the rising demand for high-precision diagnostic tools. Furthermore, the company is expected to enhance its custom service offerings, providing researchers with more flexible, bespoke solutions for drug discovery pipelines. As the biotechnology industry continues to prioritize rapid, reliable reagent supply chains, SouthernBiotech's focus on quality control and customer-centric innovation will be pivotal in maintaining its leadership status and driving long-term value for stakeholders.
See full SouthernBiotech company page
